Your browser doesn't support javascript.
loading
Flexible evaluation of surrogacy in platform studies.
Sachs, Michael C; Gabriel, Erin E; Crippa, Alessio; Daniels, Michael J.
  • Sachs MC; Department of Public Health, Section of Biostatistics, University of Copenhagen, Øster Farimagsgade 5, 1353 København K, Denmark.
  • Gabriel EE; Department of Public Health, Section of Biostatistics, University of Copenhagen, Øster Farimagsgade 5, 1353 København K, Denmark.
  • Crippa A; Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Nobels väg 12A, Stockholm 17177, Sweden.
  • Daniels MJ; Department of Statistics, University of Florida, Union Rd, Gainesville, FL 32603, USA.
Biostatistics ; 25(1): 220-236, 2023 12 15.
Article en En | MEDLINE | ID: mdl-36610075
ABSTRACT
Trial-level surrogates are useful tools for improving the speed and cost effectiveness of trials but surrogates that have not been properly evaluated can cause misleading results. The evaluation procedure is often contextual and depends on the type of trial setting. There have been many proposed methods for trial-level surrogate evaluation, but none, to our knowledge, for the specific setting of platform studies. As platform studies are becoming more popular, methods for surrogate evaluation using them are needed. These studies also offer a rich data resource for surrogate evaluation that would not normally be possible. However, they also offer a set of statistical issues including heterogeneity of the study population, treatments, implementation, and even potentially the quality of the surrogate. We propose the use of a hierarchical Bayesian semiparametric model for the evaluation of potential surrogates using nonparametric priors for the distribution of true effects based on Dirichlet process mixtures. The motivation for this approach is to flexibly model relationships between the treatment effect on the surrogate and the treatment effect on the outcome and also to identify potential clusters with differential surrogate value in a data-driven manner so that treatment effects on the surrogate can be used to reliably predict treatment effects on the clinical outcome. In simulations, we find that our proposed method is superior to a simple, but fairly standard, hierarchical Bayesian method. We demonstrate how our method can be used in a simulated illustrative example (based on the ProBio trial), in which we are able to identify clusters where the surrogate is, and is not useful. We plan to apply our method to the ProBio trial, once it is completed.
Asunto(s)
Palabras clave

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Ensayos Clínicos como Asunto Tipo de estudio: Prognostic_studies Límite: Humans Idioma: En Año: 2023 Tipo del documento: Article

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Ensayos Clínicos como Asunto Tipo de estudio: Prognostic_studies Límite: Humans Idioma: En Año: 2023 Tipo del documento: Article